{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:35:46Z","timestamp":1783719346595,"version":"3.55.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02555-7","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T12:24:25Z","timestamp":1747571065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and validation of a multiple myeloma diagnostic model based on systemic lupus erythematosus-associated genes and identification of specific genes"],"prefix":"10.1007","volume":"16","author":[{"given":"Yuepei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"issue":"1","key":"2555_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12935-024-03304-6","volume":"24","author":"H Luo","year":"2024","unstructured":"Luo H, Pan C, Wang L, Zheng L, Cao S, Hu X, Hu T, Zhao N, Shang Q, Wang J. Low TYROBP expression predicts poor prognosis in multiple myeloma. Cancer Cell Int. 2024;24(1):117.","journal-title":"Cancer Cell Int"},{"key":"2555_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2024.108220","volume":"113","author":"J Li","year":"2024","unstructured":"Li J, Dong J, Li M, Zhu H, Xin P. Potential mechanisms for predicting comorbidity between multiple myeloma and femoral head necrosis based on multiple bioinformatics. Comput Biol Chem. 2024;113: 108220.","journal-title":"Comput Biol Chem"},{"issue":"14","key":"2555_CR3","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/cncr.34778","volume":"129","author":"N Bumma","year":"2023","unstructured":"Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, et al. Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023;129(14):2179\u201391.","journal-title":"Cancer"},{"issue":"9","key":"2555_CR4","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670\u20137.","journal-title":"Lancet Haematol"},{"issue":"1","key":"2555_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","volume":"2017","author":"MV Mateos","year":"2017","unstructured":"Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. Hematology Am Soc Hematol Educ Program. 2017;2017(1):498\u2013507.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2555_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"issue":"1","key":"2555_CR7","doi-asserted-by":"publisher","first-page":"18818","DOI":"10.1038\/s41598-023-45801-0","volume":"13","author":"J Ren","year":"2023","unstructured":"Ren J, Wu M. Causal effects of genetically determined blood metabolites on multiple myeloma: a Mendelian randomization study. Sci Rep. 2023;13(1):18818.","journal-title":"Sci Rep"},{"issue":"1","key":"2555_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s43556-024-00217-8","volume":"5","author":"X Su","year":"2024","unstructured":"Su X, Yu H, Lei Q, Chen X, Tong Y, Zhang Z, Yang W, Guo Y, Lin L. Systemic lupus erythematosus: pathogenesis and targeted therapy. Molecular biomedicine. 2024;5(1):54.","journal-title":"Molecular biomedicine"},{"issue":"3","key":"2555_CR9","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.berh.2017.09.013","volume":"31","author":"MY Choi","year":"2017","unstructured":"Choi MY, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke AE. A review on SLE and malignancy. Best Pract Res Clin Rheumatol. 2017;31(3):373\u201396.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"2555_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13075-021-02648-y","volume":"23","author":"JY Han","year":"2021","unstructured":"Han JY, Kim H, Jung SY, Jang EJ, Cho SK, Sung YK. Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea. Arthritis Res Ther. 2021;23(1):270.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2555_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.25122\/jml-2023-0314","volume":"17","author":"R Desai","year":"2024","unstructured":"Desai R, Devaragudi S, Kaur L, Singh K, Bawa J, Theik NWY, Palisetti S, Jain A. SLE and multiple myeloma: an underlooked link? A review of case reports from the last decade. J Med Life. 2024;17(2):141\u20136.","journal-title":"J Med Life"},{"issue":"1","key":"2555_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.755","volume":"11","author":"L Lian","year":"2023","unstructured":"Lian L, Wang K, Xu S. Systemic lupus erythematosus associated with multiple myeloma: Two case reports and a literature review. Immun Inflamm Dis. 2023;11(1): e755.","journal-title":"Immun Inflamm Dis"},{"issue":"11","key":"2555_CR13","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.4103\/jfmpc.jfmpc_178_22","volume":"12","author":"FKM Basha","year":"2023","unstructured":"Basha FKM, Reddy VT, Sharma P, Vaishnav B. An interesting case of systemic lupus erythematosus with multiple myeloma. J Fam Med Prim Care. 2023;12(11):2970\u20132.","journal-title":"J Fam Med Prim Care"},{"key":"2555_CR14","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202006020","author":"M Kiriakidou","year":"2020","unstructured":"Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Int Med. 2020. https:\/\/doi.org\/10.7326\/AITC202006020.","journal-title":"Ann Int Med"},{"issue":"35","key":"2555_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030320","volume":"101","author":"PH Chen","year":"2022","unstructured":"Chen PH, Tung HH, Lin CH, Huang KP, Ni YL, Lin CY. A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: a CARE-compliant article. Medicine. 2022;101(35): e30320.","journal-title":"Medicine"},{"key":"2555_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2024.108268","volume":"113","author":"S Eyuboglu","year":"2024","unstructured":"Eyuboglu S, Alpsoy S, Uversky VN, Coskuner-Weber O. Key genes and pathways in the molecular landscape of pancreatic ductal adenocarcinoma: a bioinformatics and machine learning study. Comput Biol Chem. 2024;113: 108268.","journal-title":"Comput Biol Chem"},{"key":"2555_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jad.2024.05.061","volume":"359","author":"B Chen","year":"2024","unstructured":"Chen B, Sun X, Huang H, Feng C, Chen W, Wu D. An integrated machine learning framework for developing and validating a diagnostic model of major depressive disorder based on interstitial cystitis-related genes. J Affect Disord. 2024;359:22\u201332.","journal-title":"J Affect Disord"},{"key":"2555_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k601","volume":"362","author":"NM Davies","year":"2018","unstructured":"Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ Clin Res. 2018;362: k601.","journal-title":"BMJ Clin Res"},{"issue":"1","key":"2555_CR19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1186\/s12885-024-13024-9","volume":"24","author":"R Hu","year":"2024","unstructured":"Hu R, Chen F, Yu X, Li Z, Li Y, Feng S, Liu J, Li H, Shen C, Gu X, et al. Construction and validation of a prognostic model of angiogenesis-related genes in multiple myeloma. BMC Cancer. 2024;24(1):1269.","journal-title":"BMC Cancer"},{"issue":"10","key":"2555_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311419","volume":"19","author":"W Lu","year":"2024","unstructured":"Lu W, Huang H, Xu Z, Xu S, Zhao K, Xiao M. MiR-27a inhibits the growth and metastasis of multiple myeloma through regulating Th17\/Treg balance. PLoS ONE. 2024;19(10): e0311419.","journal-title":"PLoS ONE"},{"issue":"11","key":"2555_CR21","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","volume":"34","author":"CJ Neuse","year":"2020","unstructured":"Neuse CJ, Lomas OC, Schliemann C, Shen YJ, Manier S, Bustoros M, Ghobrial IM. Genome instability in multiple myeloma. Leukemia. 2020;34(11):2887\u201397.","journal-title":"Leukemia"},{"issue":"1","key":"2555_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-021-01380-0","volume":"20","author":"C Gu","year":"2021","unstructured":"Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, Wei R, Wang Y, Jurczyszyn A, Janz S, et al. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Mol Cancer. 2021;20(1):84.","journal-title":"Mol Cancer"},{"key":"2555_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145002","author":"S Akhtar","year":"2020","unstructured":"Akhtar S, Ali TA, Faiyaz A, Khan OS, Raza SS, Kulinski M, Omri HE, Bhat AA, Uddin S. Cytokine-mediated dysregulation of signaling pathways in the pathogenesis of multiple myeloma. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21145002.","journal-title":"Int J Mol Sci"},{"key":"2555_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063112","author":"YC Gau","year":"2022","unstructured":"Gau YC, Yeh TJ, Hsu CM, Hsiao SY, Hsiao HH. Pathogenesis and treatment of myeloma-related bone disease. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23063112.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2555_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;5(1):25.","journal-title":"Mol Biomed"},{"key":"2555_CR26","first-page":"539","volume":"8","author":"B Yan","year":"2015","unstructured":"Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB, Yang JR. The role of miR-29b in cancer: regulation, function, and signaling. Onco Targets Ther. 2015;8:539\u201348.","journal-title":"Onco Targets Ther"},{"key":"2555_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111738","author":"H Handa","year":"2019","unstructured":"Handa H, Murakami Y, Ishihara R, Kimura-Masuda K, Masuda Y. The role and function of microrna in the pathogenesis of multiple myeloma. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11111738.","journal-title":"Cancers"},{"key":"2555_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155401","volume":"260","author":"M Alimohammadi","year":"2024","unstructured":"Alimohammadi M, Rahimzadeh P, Khorrami R, Bonyadi M, Daneshi S, Nabavi N, Raesi R, Farani MR, Dehkhoda F, Taheriazam A, et al. A comprehensive review of the PTEN\/PI3K\/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets. Pathol Res Pract. 2024;260: 155401.","journal-title":"Pathol Res Pract"},{"issue":"4","key":"2555_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/ejh.12436","volume":"94","author":"ZY Gan","year":"2015","unstructured":"Gan ZY, Fitter S, Vandyke K, To LB, Zannettino AC, Martin SK. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. Eur J Haematol. 2015;94(4):343\u201354.","journal-title":"Eur J Haematol"},{"issue":"3","key":"2555_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.12669\/pjms.39.3.7206","volume":"39","author":"W Lu","year":"2023","unstructured":"Lu W, Liu J, Luo M, Xiao M. Relationship between monoclonal gammopathy of undetermined significance and multiple myeloma via online database analysis. Pak J Med Sci. 2023;39(3):715\u201320.","journal-title":"Pak J Med Sci"},{"issue":"1","key":"2555_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/ard.2008.096495","volume":"69","author":"AM Jacobi","year":"2010","unstructured":"Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, Burmester GR, Hiepe F, D\u00f6rner T. HLA-DRhigh\/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69(1):305\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2555_CR32","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.4049\/jimmunol.1302062","volume":"192","author":"A Caro-Maldonado","year":"2014","unstructured":"Caro-Maldonado A, Wang R, Nichols AG, Kuraoka M, Milasta S, Sun LD, Gavin AL, Abel ED, Kelsoe G, Green DR, et al. Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells. J Immunol. 2014;192(8):3626\u201336.","journal-title":"J Immunol"},{"key":"2555_CR33","doi-asserted-by":"publisher","first-page":"1155421","DOI":"10.3389\/fimmu.2023.1155421","volume":"14","author":"S Iwata","year":"2023","unstructured":"Iwata S, Hajime Sumikawa M, Tanaka Y. B cell activation via immunometabolism in systemic lupus erythematosus. Front Immunol. 2023;14:1155421.","journal-title":"Front Immunol"},{"issue":"1","key":"2555_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2016.04.024","volume":"377","author":"K De Veirman","year":"2016","unstructured":"De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, et al. Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Lett. 2016;377(1):17\u201324.","journal-title":"Cancer Lett"},{"issue":"1","key":"2555_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341.","journal-title":"Immunity"},{"issue":"1","key":"2555_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10238-023-01277-w","volume":"24","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Li F, Li J, Xia Y, Wang J, Chen L. An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma. Clin Exp Med. 2024;24(1):16.","journal-title":"Clin Exp Med"},{"key":"2555_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.642285","volume":"12","author":"TD Ricketts","year":"2021","unstructured":"Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E. Mechanisms of macrophage plasticity in the tumor environment: manipulating activation state to improve outcomes. Front Immunol. 2021;12: 642285.","journal-title":"Front Immunol"},{"issue":"6","key":"2555_CR38","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","volume":"22","author":"MME de Jong","year":"2021","unstructured":"de Jong MME, Kellermayer Z, Papazian N, Tahri S, Hofste Op Bruinink D, Hoogenboezem R, Sanders MA, van de Woestijne PC, Bos PK, Khandanpour C, et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol. 2021;22(6):769\u201380.","journal-title":"Nat Immunol"},{"issue":"9","key":"2555_CR39","first-page":"806","volume":"17","author":"Y Kawano","year":"2017","unstructured":"Kawano Y, Roccaro AM, Ghobrial IM, Azzi J. Multiple Myeloma and the Immune Microenvironment. Curr Cancer Drug Targets. 2017;17(9):806\u201318.","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"2555_CR40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/leu.2012.272","volume":"27","author":"Y Zheng","year":"2013","unstructured":"Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, Liu Z, Li H, He J, et al. PSGL-1\/selectin and ICAM-1\/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013;27(3):702\u201310.","journal-title":"Leukemia"},{"issue":"4","key":"2555_CR41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000443275","volume":"168","author":"R Vyzoukaki","year":"2015","unstructured":"Vyzoukaki R, Tsirakis G, Pappa CA, Devetzoglou M, Tzardi M, Alexandrakis MG. The impact of mast cell density on the progression of bone disease in multiple myeloma patients. Int Arch Allergy Immunol. 2015;168(4):263\u20138.","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"2555_CR42","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/rheumatology\/keu434","volume":"54","author":"MF Ugarte-Gil","year":"2015","unstructured":"Ugarte-Gil MF, S\u00e1nchez-Z\u00fa\u00f1iga C, Gamboa-C\u00e1rdenas RV, Aliaga-Zamudio M, Zevallos F, Tineo-Pozo G, Cucho-Venegas JM, Mosqueira-Riveros A, Perich-Campos RA, Alfaro-Lozano JL, et al. Circulating naive and memory CD4+ T cells and metabolic syndrome in patients with systemic lupus erythematosus: data from a primarily Mestizo population. Rheumatology (Oxford). 2015;54(7):1302\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"21","key":"2555_CR43","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1182\/blood.V124.21.2097.2097","volume":"124","author":"S Lub","year":"2014","unstructured":"Lub S, Maes A, Maes K, De Veirman K, Leleu X, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh EJB. Targeting the anaphase promoting complex\/Cyclosome (APC\/C) in multiple myeloma. Blood. 2014;124(21):2097.","journal-title":"Blood"},{"key":"2555_CR44","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12935-020-01355-z","volume":"20","author":"Y Peng","year":"2020","unstructured":"Peng Y, Wu D, Li F, Zhang P, Feng Y, He A. Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis. Cancer Cell Int. 2020;20:262.","journal-title":"Cancer Cell Int"},{"issue":"24","key":"2555_CR45","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1182\/blood-2015-10-673095","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, Barrio S, Sanchez ML, Alignani D, Lasa M, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127(24):3035\u20139.","journal-title":"Blood"},{"key":"2555_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155851","volume":"153","author":"I Serin","year":"2022","unstructured":"Serin I, Oyaci Y, Pehlivan M, Pehlivan S. Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms. Cytokine. 2022;153: 155851.","journal-title":"Cytokine"},{"issue":"4","key":"2555_CR47","doi-asserted-by":"publisher","first-page":"601","DOI":"10.7150\/ijms.91506","volume":"21","author":"J Ma","year":"2024","unstructured":"Ma J, Liu D, Mao X, Huang L, Ren Y, Xu X, Huang X, Deng C, Shi F, Sun P. Enhanced diagnostic efficiency of endometrial carcinogenesis and progression in women with abnormal uterine bleeding through peripheral blood cytokine testing: a multicenter retrospective cohort study. Int J Med Sci. 2024;21(4):601\u201311.","journal-title":"Int J Med Sci"},{"issue":"24","key":"2555_CR48","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.4161\/cc.9.24.14322","volume":"9","author":"HW Wang","year":"2010","unstructured":"Wang HW, Joyce JA. Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell cycle (Georgetown, Tex). 2010;9(24):4824\u201335.","journal-title":"Cell cycle (Georgetown, Tex)"},{"key":"2555_CR49","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.3389\/fimmu.2019.02638","volume":"10","author":"C Fu","year":"2019","unstructured":"Fu C, Jiang L, Hao S, Liu Z, Ding S, Zhang W, Yang X, Li S. Activation of the IL-4\/STAT6 signaling pathway promotes lung cancer progression by increasing M2 myeloid cells. Front Immunol. 2019;10:2638.","journal-title":"Front Immunol"},{"key":"2555_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/biom14091095","author":"M Koz\u0142owski","year":"2024","unstructured":"Koz\u0142owski M, Borzyszkowska D, Lerch N, Turo\u0144-Skrzypi\u0144ska A, Tkacz M, Lubikowski J, Tarnowski M, Rotter I, Cymbaluk-P\u0142oska A. IL-4, IL-7, IL-9, NT, NRP1 may be useful markers in the diagnosis of endometrial cancer. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14091095.","journal-title":"Biomolecules"},{"issue":"1","key":"2555_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1634\/stemcells.2005-0116","volume":"24","author":"GA Challen","year":"2006","unstructured":"Challen GA, Little MH. A side order of stem cells: the SP phenotype. Stem cells (Dayton, Ohio). 2006;24(1):3\u201312.","journal-title":"Stem cells (Dayton, Ohio)"},{"issue":"17","key":"2555_CR52","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1182\/blood-2010-02-267344","volume":"117","author":"J Jakubikova","year":"2011","unstructured":"Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117(17):4409\u201319.","journal-title":"Blood"},{"issue":"14","key":"2555_CR53","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1158\/0008-5472.CAN-05-0592","volume":"65","author":"L Patrawala","year":"2005","unstructured":"Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Can Res. 2005;65(14):6207\u201319.","journal-title":"Can Res"},{"issue":"19","key":"2555_CR54","doi-asserted-by":"publisher","first-page":"7742","DOI":"10.1158\/0008-5472.CAN-07-5882","volume":"68","author":"T Chiba","year":"2008","unstructured":"Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y, Yonemitsu Y, Yokosuka O, Taniguchi H, Nakauchi H, et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Can Res. 2008;68(19):7742\u20139.","journal-title":"Can Res"},{"issue":"3","key":"2555_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056954","volume":"8","author":"M Nara","year":"2013","unstructured":"Nara M, Teshima K, Watanabe A, Ito M, Iwamoto K, Kitabayashi A, Kume M, Hatano Y, Takahashi N, Iida S, et al. Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells. PLoS ONE. 2013;8(3): e56954.","journal-title":"PLoS ONE"},{"key":"2555_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz104","author":"JN Hofmann","year":"2020","unstructured":"Hofmann JN, Landgren O, Landy R, Kemp TJ, Santo L, McShane CM, Shearer JJ, Lan Q, Rothman N, Pinto LA, et al. A prospective study of circulating chemokines and angiogenesis markers and risk of multiple myeloma and its precursor. JNCI Cancer Spectr. 2020. https:\/\/doi.org\/10.1093\/jncics\/pkz104.","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"2555_CR57","doi-asserted-by":"publisher","first-page":"2335421","DOI":"10.1080\/16078454.2024.2335421","volume":"29","author":"W Zhang","year":"2024","unstructured":"Zhang W, Chen X, Wang Z, Wang Q, Feng J, Wang D, Wang Z, Tang J, Qing S, Zhang Y. Identification of HIST1H2BH as the hub gene associated with multiple myeloma using integrated bioinformatics analysis. Hematology. 2024;29(1):2335421.","journal-title":"Hematology"},{"issue":"1","key":"2555_CR58","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-018-0689-y","volume":"12","author":"S Raimondo","year":"2019","unstructured":"Raimondo S, Saieva L, Vicario E, Pucci M, Toscani D, Manno M, Raccosta S, Giuliani N, Alessandro R. Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis. J Hematol Oncol. 2019;12(1):2.","journal-title":"J Hematol Oncol"},{"key":"2555_CR59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.omto.2020.10.004","volume":"19","author":"M Li","year":"2020","unstructured":"Li M, Qi L, Xu JB, Zhong LY, Chan S, Chen SN, Shao XR, Zheng LY, Dong ZX, Fang TL, et al. Methylation of the promoter region of the tight junction protein-1 by DNMT1 induces EMT-like features in multiple myeloma. Mol Ther Oncol. 2020;19:197\u2013207.","journal-title":"Mol Ther Oncol"},{"key":"2555_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.966817","volume":"12","author":"J Jia","year":"2022","unstructured":"Jia J, Han Z, Wang X, Zheng X, Wang S, Cui Y. H2B gene family: a prognostic biomarker and correlates with immune infiltration in glioma. Front Oncol. 2022;12: 966817.","journal-title":"Front Oncol"},{"issue":"1","key":"2555_CR61","doi-asserted-by":"publisher","first-page":"16495","DOI":"10.1038\/s41598-017-16472-5","volume":"7","author":"X Li","year":"2017","unstructured":"Li X, Tian R, Gao H, Yang Y, Williams BRG, Gantier MP, McMillan NAJ, Xu D, Hu Y, Gao Y. Identification of a histone family gene signature for predicting the prognosis of cervical cancer patients. Sci Rep. 2017;7(1):16495.","journal-title":"Sci Rep"},{"issue":"3","key":"2555_CR62","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/tox.23034","volume":"36","author":"Z Zeng","year":"2021","unstructured":"Zeng Z, Lu J, Wu D, Zuo R, Li Y, Huang H, Yuan J, Hu Z. Poly(ADP-ribose) glycohydrolase silencing-mediated H2B expression inhibits benzo(a)pyrene-induced carcinogenesis. Environ Toxicol. 2021;36(3):291\u20137.","journal-title":"Environ Toxicol"},{"issue":"2","key":"2555_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031286","volume":"7","author":"HP Lin","year":"2012","unstructured":"Lin HP, Jiang SS, Chuu CP. Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells. PLoS ONE. 2012;7(2): e31286.","journal-title":"PLoS ONE"},{"issue":"9","key":"2555_CR64","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1182\/bloodadvances.2022007383","volume":"7","author":"TA Bloedjes","year":"2023","unstructured":"Bloedjes TA, de Wilde G, Khan GH, Ashby TC, Shaughnessy JD, Zhan F, Houtkooper RH, Bende RJ, van Noesel CJM, Spaargaren M, et al. AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity. Blood Adv. 2023;7(9):1697\u2013712.","journal-title":"Blood Adv"},{"issue":"10","key":"2555_CR65","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/biology13100844","volume":"13","author":"CD Wesley","year":"2024","unstructured":"Wesley CD, Sansonetti A, Neutel CHG, Kr\u00fcger DN, De Meyer GRY, Martinet W, Guns PJ. Short-term proteasome inhibition: assessment of the effects of carfilzomib and bortezomib on cardiac function, arterial stiffness, and vascular reactivity. Biology. 2024;13(10):2.","journal-title":"Biology"},{"issue":"4","key":"2555_CR66","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/path.4860","volume":"241","author":"N De Beule","year":"2017","unstructured":"De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, et al. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation. J Pathol. 2017;241(4):534\u201346.","journal-title":"J Pathol"},{"key":"2555_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110171","volume":"88","author":"R Ramezankhani","year":"2021","unstructured":"Ramezankhani R, Minaei N, Haddadi M, Solhi R, Taleahmad S. The impact of sex on susceptibility to systemic lupus erythematosus and rheumatoid arthritis; a bioinformatics point of view. Cell Signal. 2021;88: 110171.","journal-title":"Cell Signal"},{"issue":"1","key":"2555_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","volume":"105","author":"Y Komohara","year":"2014","unstructured":"Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014;105(1):1\u20138.","journal-title":"Cancer Sci"},{"key":"2555_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107224","volume":"163","author":"C Xie","year":"2023","unstructured":"Xie C, Zhong L, Luo J, Luo J, Wu Y, Zheng S, Jiang L, Zhang J, Shi Y. Identification of mutation gene prognostic biomarker in multiple myeloma through gene panel exome sequencing and transcriptome analysis in Chinese population. Comput Biol Med. 2023;163: 107224.","journal-title":"Comput Biol Med"},{"issue":"1","key":"2555_CR70","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","volume":"14","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, et al. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024;14(1):194.","journal-title":"Blood Cancer J"},{"key":"2555_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094462","author":"N Giannakoulas","year":"2021","unstructured":"Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22094462.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2555_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063745","volume":"8","author":"V Kari","year":"2013","unstructured":"Kari V, Karpiuk O, Tieg B, Kriegs M, Dikomey E, Krebber H, Begus-Nahrmann Y, Johnsen SA. A subset of histone H2B genes produces polyadenylated mRNAs under a variety of cellular conditions. PLoS ONE. 2013;8(5): e63745.","journal-title":"PLoS ONE"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02555-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02555-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T14:02:04Z","timestamp":1747576924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02555-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2555"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02555-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,18]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adheres to local legislation and institutional requirements, and does not require approval from an institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"803"}}